COMMUNIQUÉS West-GlobeNewswire

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
11/11/2025
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, [...]
Coloplast A/S - Notice of Annual General Meeting 2025
11/11/2025
Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen [...]
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology
11/11/2025
MILPITAS, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSCs [...]
RadNet Acquires CIMAR UK, Empowering DeepHealth to Accelerate AI-Powered Imaging, Reporting and Image-Based Screening
11/11/2025
Acquisition supplements CIMAR’s cloud-native infrastructure with DeepHealth’s AI-powered informatics to deliver connected, efficient and accessible care LOS ANGELES and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- RadNet, [...]
Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma
11/11/2025
225Ac-SSO110 has received U.S. FDA Orphan Drug Designation Initial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026 Potential to address a broad range of neuroendocrine cancers BERLIN, Nov. 11, 2025 ( [...]
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
11/11/2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an [...]
MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results
11/11/2025
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
La Croix-Rouge canadienne déploie une clinique médicale d’urgence en Jamaïque
11/11/2025
Des spécialistes humanitaires sont mobilisés pour porter secours aux personnes touchées par l’ouragan Melissa OTTAWA, Ontario, 10 nov. 2025 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne, en collaboration avec la [...]
Canadian Red Cross sending emergency medical clinic to Jamaica
11/11/2025
Humanitarian experts deploying to help people impacted by Hurricane Melissa OTTAWA, Ontario, Nov. 10, 2025 (GLOBE NEWSWIRE) -- In response to the devastating impact of Hurricane Melissa across the Caribbean region, the [...]
Regional Health Properties, Inc. Reports Sale of Skilled Nursing Facility
10/11/2025
Atlanta, GA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional,” the “Company,” “we,” “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB: RHEPZ) today announced the completion [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
10/11/2025
COPENHAGEN, Denmark, November 10, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94 [...]
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
10/11/2025
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy [...]
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
10/11/2025
Fireside chat scheduled for Wednesday November 12, 2025 at 10:00 AM ET NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and [...]
MIMEDX to Participate in Upcoming Investor Conferences
10/11/2025
MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
10/11/2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has [...]
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
10/11/2025
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027 LONDON, [...]
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025) Pending the results of the topline data from the HOPE-3 [...]
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control [...]
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
10/11/2025
WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases [...]

Pages